


Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-497E9229-A17D-4947-95B5-595C5101B84B_4_en-US
DOI: https://doi.org/10.31003/USPNF_M68990_04_01
DOI Ref: evj9m

© 2025 USPC
Do not distribute

Prilocaine Hydrochloride



$C_{13}H_{20}N_2O \cdot HCl$ 256.77

Propanamide, *N*-(2-methylphenyl)-2-(propylamino)-, monohydrochloride;
2-(Propylamino)-o-propionotoluidide monohydrochloride CAS RN®: 1786-81-8; UNII: MJW015BAPH.

DEFINITION

Prilocaine Hydrochloride contains NLT 98.0% and NMT 102.0% of prilocaine hydrochloride ($C_{13}H_{20}N_2O \cdot HCl$), calculated on the dried basis.

IDENTIFICATION

Change to read:

- A. **[▲ SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy: 197K](#)** ▲ (CN 1-MAY-2020)
- B. **[IDENTIFICATION TESTS—GENERAL, Chloride\(191\)](#)**

Analysis: Dissolve 100 mg in 3 mL of water, render the solution alkaline with 6 N ammonium hydroxide, and filter.

Acceptance criteria: The filtrate meets the requirements.

- C. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Buffer: 0.18 g/L of monobasic sodium phosphate and 2.89 g/L of dibasic sodium phosphate dihydrate in water

Mobile phase: Acetonitrile and *Buffer* (26:74)

System suitability solution: 3 µg/mL each of [USP Prilocaine Hydrochloride RS](#) and [USP Prilocaine Related Compound B RS](#) in *Mobile phase*

Standard solution: 0.3 mg/mL of [USP Prilocaine Hydrochloride RS](#) in *Mobile phase*

Sample solution: 0.3 mg/mL of Prilocaine Hydrochloride in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 240 nm

Column: 4.6-mm × 15-cm; 5-µm packing L1

Flow rate: 1 mL/min

Injection volume: 20 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

[**NOTE**—See [Table 1](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 3.0 between prilocaine and prilocaine related compound B, *System suitability solution*

Tailing factor: NMT 1.5, *Standard solution*

Relative standard deviation: NMT 0.73, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of prilocaine hydrochloride ($C_{13}H_{20}N_2O \cdot HCl$) in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of prilocaine from the *Sample solution* r_S = peak response of prilocaine from the *Standard solution* C_S = concentration of [USP Prilocaine Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** 98.0%–102.0% on the dried basis**IMPURITIES**• [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%• **ORGANIC IMPURITIES****Buffer, Mobile phase, System suitability solution, and Chromatographic system:** Proceed as directed in the Assay.**Standard solution 1:** 3 µg/mL of [USP Prilocaine Hydrochloride RS](#) in *Mobile phase***Standard solution 2:** 0.4 µg/mL of [USP Prilocaine Related Compound A RS](#) in *Mobile phase***Sample solution:** 3 mg/mL of Prilocaine Hydrochloride in *Mobile phase***System suitability****Samples:** *System suitability solution* and *Standard solution 2*[NOTE—See [Table 1](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 3.0 between prilocaine and prilocaine related compound B, *System suitability solution***Signal-to-noise ratio:** NLT 10 for prilocaine related compound A, *Standard solution 2***Analysis****Samples:** *Standard solution 1*, *Standard solution 2*, and *Sample solution*

Calculate the percentage of prilocaine related compound A in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of prilocaine related compound A from the *Sample solution* r_S = peak response of prilocaine related compound A from *Standard solution 2* C_S = concentration of [USP Prilocaine Related Compound A RS](#) in *Standard solution 2* (mg/mL) C_U = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Prilocaine Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of any unspecified impurity from the *Sample solution* r_S = peak response of prilocaine from *Standard solution 1* C_S = concentration of [USP Prilocaine Hydrochloride RS](#) in *Standard solution 1* (mg/mL) C_U = concentration of Prilocaine Hydrochloride in the *Sample solution* (mg/mL)**Acceptance criteria:** See [Table 1](#). The reporting level for impurities is 0.05%.**Table 1**

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|-------------------------------|-------------------------|------------------------------|
| Prilocaine related compound A | 0.3 | 0.01 |
| Prilocaine | 1.0 | — |

| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|-------------------------------------|-------------------------|------------------------------|
| Prilocaine related compound B | 1.2 | — |
| Any individual unspecified impurity | — | 0.10 |
| Total impurities | — | 0.2 |

SPECIFIC TESTS

- [Loss on Drying \(731\)](#).

Analysis: Dry a sample at 105° for 4 h.

Acceptance criteria: NMT 0.3%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. Store at room temperature.

- [USP Reference Standards \(11\)](#).

[USP Prilocaine Hydrochloride RS](#)

[USP Prilocaine Related Compound A RS](#)

o-Toluidine hydrochloride.

$C_7H_9N \cdot HCl$ 143.62

[USP Prilocaine Related Compound B RS](#)

(RS)-N-(4-Methylphenyl)-2-(propylamino)propanamide.

$C_{13}H_{20}N_2O$ 220.31

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|----------------------------|---|---------------------------|
| PRILOCAINE HYDROCHLORIDE | Documentary Standards Support | SM52020 Small Molecules 5 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM52020 Small Molecules 5 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(6)

Current DocID: GUID-497E9229-A17D-4947-95B5-595C5101B84B_4_en-US

DOI: https://doi.org/10.31003/USPNF_M68990_04_01

DOI ref: [evj9m](#)